Etuvetidigene Autotemcel 治疗 Wiskott-Aldrich 综合征
该研究整合两项前瞻性开放标签临床研究(1-2 期 8 例、3 期 10 例)及扩展可及项目(9 例),评估 etu-cel 治疗 Wiskott-Aldrich 综合征的疗效与安全性;中位随访 5.7 年,1 年和 5 年总生存率均为 96%,严重感染和出血事件率较治疗前下降,结论支持持续临床获益。
要点
- etu-cel 治疗后 1 年与 5 年总生存率均为 96%。
- 严重感染年发生率由治疗前 2.00 降至治疗后 0.15。
- 中重度出血年发生率由治疗前 2.00 降至治疗后 0.80。
核心结论
- etu-cel 对 Wiskott-Aldrich 综合征患者显示出持续临床获益。
研究设计与样本
- 整合两项前瞻性开放标签临床研究(1-2 期 8 例、3 期 10 例)及扩展可及项目 9 例。
- 患者接受利妥昔单抗和减低强度预处理后单次静脉输注 etu-cel。
主要发现
- 存活参与者中位随访 5.7 年(范围 2.3 至 13.3),基因治疗时中位年龄 2.6 岁(范围 1.0 至 35.1)。
- 1 年和 5 年总生存率均为 96%,1 例死亡。
- 最常见的 3 级及以上不良事件为中心静脉导管相关感染,未观察到插入性致癌证据。
- 严重感染每人年发生率从治疗前 2.00(95%CI 1.50 至 2.61)降至治疗后 6 个月以上至 18 个月期间 0.15(95%CI 0.04 至 0.39)。
- 中重度出血事件每人年发生率从治疗前 2.00(95%CI 1.50 至 2.61)降至治疗后 1 年 0.80(95%CI 0.49 至 1.22)。
临床怎么用
- etu-cel 可作为 Wiskott-Aldrich 综合征患者的一种自体基因治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Wiskott-Aldrich syndrome is a rare, X-linked, life-threatening inborn error of immunity and platelet disorder caused by variants in the gene WAS. Etuvetidigene autotemcel (etu-cel) is an autologous gene therapy consisting of hematopoietic stem and progenitor cells that have been transduced ex vivo with a lentiviral vector encoding WAS complementary DNA. METHODS: We integrated data from two prospective open-label clinical studies (a phase 1-2 study with 8 participants and a phase 3 study with 10 participants) and an expanded-access program with 9 participants to evaluate the efficacy and safety of etu-cel in patients with Wiskott-Aldrich syndrome. The participants received a single intravenous infusion of etu-cel after rituximab administration and reduced-intensity conditioning. The primary efficacy end points were overall survival, severe infections from 6 to 18 months after gene therapy, and moderate and severe bleeding events in the first 12 months after gene therapy. Results for severe infections and moderate and severe bleeding are reported as the rate of events (number per person-year of observation), which was compared with the rate in the year before gene therapy. RESULTS: The median follow-up among the surviving participants was 5.7 years (range, 2.3 to 13.3), and the median age at the time of gene therapy was 2.6 years (range, 1.0 to 35.1). Overall survival at both 1 year and 5 years was 96%; one participant died. The most common adverse event of grade 3 or higher was central venous catheter-related infection. No evidence of insertional oncogenesis was observed. The rate of severe infections per person-year of observation decreased from 2.00 (95% confidence interval [CI], 1.50 to 2.61) in the year before gene therapy to 0.15 (95% CI, 0.04 to 0.39) in the period beyond 6 months up to 18 months after treatment. The rate of moderate or severe bleeding events per person-year of observation decreased from 2.00 (95% CI, 1.50 to 2.61) in the year before gene therapy to 0.80 (95% CI, 0.49 to 1.22) in the year after treatment. CONCLUSIONS: Our results show that the effects of etu-cel are consistent with a sustained clinical benefit in persons with Wiskott-Aldrich syndrome. (Funded by Fondazione Telethon and others; TIGET-WAS and OTL-103-4 ClinicalTrials.gov numbers, NCT01515462 and NCT03837483, respectively.).
引用
- Ferrua F, Cenciarelli S, Giannelli S, et al. Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome. N Engl J Med. 2026. PMID: 42777242. doi:10.1056/NEJMoa2515005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。